Skip to Content

Icosapent Pregnancy and Breastfeeding Warnings

Icosapent is also known as: Vascepa

Medically reviewed on Feb 28, 2017

Icosapent Pregnancy Warnings

Icosapent has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of decreased fetal survival, teratogenicity (visceral or skeletal abnormalities, absence of optic nerve, and testes atrophy), and female fertility impairment (decreased copulation rate, delayed estrus, and decreased implantations). There are no controlled data in human pregnancy. The manufacturer recommends that icosapent should only be used during pregnancy when the potential benefits outweigh the potential risks to the developing fetus.

See references

Icosapent Breastfeeding Warnings

Omega-3-acid ethyl esters are excreted in human milk. Icosapent's effects in the nursing infant are unknown. The manufacturer recommends exercising caution when administering icosapent to nursing women.

See references

References for pregnancy information

  1. "Product Information. Vascepa (icosapent)." Amarin Pharmaceuticals Inc, Warren, NJ.

References for breastfeeding information

  1. "Product Information. Vascepa (icosapent)." Amarin Pharmaceuticals Inc, Warren, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide